Last reviewed · How we verify

Botulinum toxin B

United States Department of Defense · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 5/100

Botulinum toxin B is a Small molecule drug developed by United States Department of Defense. It is currently FDA-approved. Also known as: Myobloc.

Botulinum toxin B is a neurotoxic protein that prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, causing flaccid paralysis. It has been studied as a potential treatment for various conditions, including Overactive Bladder, Urinary Urge Incontinence, and Dystonic Tremor Syndrome, among others.

At a glance

Generic nameBotulinum toxin B
Also known asMyobloc
SponsorUnited States Department of Defense
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Botulinum toxin B

What is Botulinum toxin B?

Botulinum toxin B is a Small molecule drug developed by United States Department of Defense.

Who makes Botulinum toxin B?

Botulinum toxin B is developed and marketed by United States Department of Defense (see full United States Department of Defense pipeline at /company/united-states-department-of-defense).

Is Botulinum toxin B also known as anything else?

Botulinum toxin B is also known as Myobloc.

What development phase is Botulinum toxin B in?

Botulinum toxin B is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing